Manganese chloride tetrahydrate - Ascelia Pharma
Alternative Names: CMC-001; Mangoral; OrviglanceLatest Information Update: 16 Aug 2023
At a glance
- Originator CMC Contrast
- Developer Ascelia Pharma
- Class Contrast media; Heavy metals
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Liver disorders
Most Recent Events
- 09 Aug 2023 Ascelia Pharma plans to discuss with the FDA regarding the significant intra-reader variability observed in image scoring in the phase III SPARKLE trial
- 21 Jun 2023 Safety and efficacy data from a open-label trial in hepatically impaired participants was presented at the European Association for the Study of the Liver Congress, 2023 (EASL-2023)
- 27 Feb 2023 Ascelia Pharma completes a phase III SPARKLE trial in Liver disorders (Diagnosis) in the US, Argentina, Colombia, Germany, Italy, Mexico, Poland, Russia, Sweden and Turkey (PO) (NCT04119843)